Table 5. Comparison of the present study data with previous RI studies.
|
ANALYTE (unit) |
Gender |
PS | MC | R1 | R2 | R3 | MEV |
|---|---|---|---|---|---|---|---|
|
LL–UL |
LL–UL |
LL–UL |
LL–UL |
LL–UL |
LL–UL |
||
| ALP (U/L) |
M |
40–127 (*, #) |
42–120 |
64–176 |
36–129 |
44–134 |
40–130 |
| F |
40–116 (*, #) |
36–110 |
51–141 |
31–120 |
44–134 |
35–105 |
|
| GGT (U/L) |
M |
9–58 (*, #) |
11–58 |
6.5–34.1 |
8–61 |
||
| F |
7–32 (*, #) |
7–27 |
6.0–26.4 |
5–36 |
|||
| AST (U/L) |
M |
9–28 (*, #) |
13–36 |
10–45 |
12–32 |
5–40 |
|
| F |
9–24 (*, #) |
11–28 |
9–32 |
10–28 |
5–32 |
||
| ALT (U/L) |
M |
10–55 (*, #) |
7–38 |
8–45 |
6–44 |
5–41 |
|
| F |
6–30 (*, #) |
7–23 |
6–26 |
3–40 |
5–33 |
||
| LDH (U/L) |
M |
104–212 (*, #) |
126–231 |
190–364 |
135–225 |
||
| F |
105–202 (*, #) |
120–231 |
190–364 |
135–214 |
|||
| AMY (U/L) |
M |
34–131 (*, #) |
31–121 |
21–90 |
28–100 |
||
| F |
23–116 (*, #) |
32–117 |
21–90 |
||||
| CK (U/L) |
M |
42–228 (*, #) |
47–252 |
67–266 |
7–190 |
||
| F |
31–142 (*, #) |
32–135 |
43–220 |
7–170 |
|||
| TG (mmol/L) |
M |
0.59–3.12 (*, #) |
0.52–3.47 |
0.39–3.37 |
0.45–2.44 |
0.57–3.54 |
< 1.69‡ |
| F |
0.63–2.71 (*, #) |
0.46–2.39 |
0.27–2.47 |
0.41–1.95 |
0.44–2.25 |
||
| TC (mmol/L) |
M |
3.02–6.68 (*, #) |
3.15–6.17 |
2.64–6.63 |
2.87–6.29 |
3.13–6.97 |
< 5.18‡ |
| F |
2.90–6.53 (*, #) |
3.25–5.92 |
2.64–6.63 |
2.87–6.29 |
3.13–6.97 |
||
| HDL–C (mmol/L) |
M |
0.54–1.30 (*, #) |
0.77–1.57 |
0.77–1.39 |
0.73–1.74 |
0.8–1.71 |
> 1.5‡ |
| F |
0.72–2.02 (*, #) |
0.92–1.97 |
0.80–2.15 |
0.91–2.15 |
0.91–2.02 |
||
| LDL–C (mmol/L) |
M |
1.49–4.98 (*, #) |
1.52–4.25 |
1.06–4.56 |
1.55–4.77 |
< 2.5‡ |
|
| F |
1.45–4.48 (*, #) |
1.27–3.87 |
1.06–4.56 |
1.55–4.77 |
|||
| Ca (mmol/L) |
M |
2.1–2.5 |
2.17–2.5 |
2.20–2.60 |
2.28–2.64 |
2.15–2.55 |
|
| F |
2.1–2.5 |
2.12–2.47 |
2.18–2.63 |
2.16–2.57 |
|||
| IP (mmol/L) |
M |
0.76–1.51 |
0.76–1.4 |
0.74–1.52 |
0.8–1.45 |
||
| F |
0.85–1.39 (*, #) |
0.83 – 1.4 |
0.74–1.52 |
||||
| Mg (mmol/L) |
M |
0.70–0.90 (*, #) |
0.82–1.1 |
0.66–1.03 |
0.7–1.07 |
||
| F |
0.68–0.89 (*, #) |
0.82–1.1 |
0.66–1.03 |
||||
| Fe (µmol/L) |
M |
8.5–30.1 (*, #) |
7.3–31.1 |
5.83–34.5 |
|||
| F |
5.2–27.8 (*, #) |
4.9–30.1 |
|||||
| TP (g/L) |
M |
62–79 (*) |
67–82 |
61–80 |
66–87 |
||
| F |
62–78 (*) |
66–82 |
61–80 |
||||
| ALB (g/L) |
M |
42–50 (#) |
41–50 |
37–51 |
35–52 |
||
| F |
38–50 |
40–49 |
37–51 |
||||
| TBIL (µmol/L) |
M |
3.8–23.9 (*, #) |
3.6–23.9 |
5.1–25.7 |
1.71–20.5 |
||
| F |
3.1–20.7 (*, #) |
3.4–17.1 |
3.4–18.8 |
||||
|
ANALYTE (unit) |
Gender |
PS |
MC |
R1 |
R2 |
R3 |
MEV |
|
LL–UL |
LL–UL |
LL–UL |
LL–UL |
LL–UL |
LL–UL |
||
| DBIL (µmol/L) |
M |
1.20–5.30 (*, #) |
1.71–8.50 |
1.71–10.26 |
1.54–5.13 |
||
| F |
1.10–4.60 (*, #) |
1.71–6.84 |
0.68–7.01 |
||||
| GLU (mmol/L) |
M |
3.7–6.1 (#) |
3.9–5.9 |
3.55–5.60 |
4.00–5.83 |
< 5.5‡ |
|
| F |
3.9–6.3 (*, #) |
3.8–5.6 |
3.55–5.60 |
4.00–5.83 |
|||
| UN (mmol/L) |
M |
3.10–7.20 (*, #) |
2.87–7.41 |
2.66–6.83 |
2.83–8.15 |
2.86–6.78 |
3.16–7.34 |
| F |
2.30–6.90 (*, #) |
2.21–6.78 |
2.00–6.17 |
2.14–6.78 |
2.14–6.07 |
2.5–6.7 |
|
| CRE (µmol/L) |
M |
59–107 (*, #) |
58–89 |
62–133 |
80–142 |
71–101 |
62–106 |
| F |
45–83 (*, #) |
51–69 |
44–106 |
62–115 |
56–92 |
44–80 |
|
| UA (µmol/L) |
M |
202–489 (*, #) |
213–476 |
160–350 |
220–480 |
202–417 |
|
| F |
148–369 (*, #) |
148–363 |
60–240 |
130–380 |
143–339 |
||
| Na (mmol/L) |
M |
134–147 |
137–144 |
133–151 |
139–147 |
136–145 |
|
| F |
134–146 |
137–144 |
133–151 |
139–147 |
|||
| K (mmol/L) |
M |
3.7–5.1 (*) |
3.7–5.0 |
3.4–5.0 |
3.7-5.7 |
3.5–5.5 |
|
| F |
3.8–5.1 (#) |
3.7–5.0 |
3.4–5.0 |
3.6-5.07 |
|||
| Cl (mmol/L) |
M |
96–108 |
98–107 |
97–108 |
103-111 |
98–107 |
|
| F |
98–108 |
100–107 |
97–108 |
103-111 |
|||
| FT3 (pmol/L) |
M |
3.7–6.0 (*, #) |
2.00-6.77 |
4.57-8.02 |
3.1–6.8 |
||
| F |
3.1–6.2 (*, #) |
2.00-6.77 |
4.57-8.02 |
||||
| FT4 (pmol/L) |
M |
11.9–20.4 (*, #) |
10.29-24.45 |
13.2-25.0 |
12.00–21.93 |
||
| F |
11.3–20.9 (*, #) |
10.29-24.45 |
13.2-25.0 |
||||
| TSH (mU/L) |
M |
0.36–4.78 (*, #) |
0.51–3.51 |
0.30-4.17 |
0.60-6.25 |
0.27–4.2 |
|
| F |
0.49–4.92 (*, #) |
0.51–3.51 |
0.30-4.17 |
0.60-6.25 |
|||
| VIT B12 (pmol/L) |
M |
70–368 (*, #) |
158–1139 |
142-953 |
14 1–489 |
||
| F |
71–395 (*, #) |
235–1473 |
142-953 |
||||
| FOL (nmol/L) |
M |
9–28 (*, #) |
6.7–39.4 |
12.7-45.3 |
7.02–39.64 |
||
| F |
9–33 (*, #) |
8.2–49.8 |
12.7-45.3 |
||||
| FER (µg/L) |
M |
46–399 (*, #) |
10–190 |
30–400 |
|||
| F |
15–209 (*, #) |
3.2–56 |
13–150 |
||||
| PTH (pmol/L) |
M |
1.8–8.1 (*, #) |
1.58–6.84 |
||||
| F |
1.9–11.9 (*, #) |
||||||
| INS (pmol/L) |
M |
21–190 (#) |
17.8–173 |
||||
| F |
26–161 (#) |
||||||
| LL – lower limit, UL – upper limit, PS – present study, R1 – RIs investigated in the region of Bursa and presented by Ilcol and Aslan (19), R2 – RIs investigated in the region of Denizli by Enli et al. (20), R3 – RIs investigated in the region of Izmir by Koseoglu et al. (21), MC – global, multicenter RIs for Turkey (11), MEV – manufacturer expected values, M – male, F – female, (‡) – clinical decision limits for TG, TC, HDL-C, LDL-C and GLU, (*) – UL of PS different (> 10% lower or higher) from MC, R1, R2, R3 or MEV, (#) – LL of PS different (>10% lower or higher) from MC, R1, R2, R3 or MEV. | |||||||